drugset / Trial / NCT05845567
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
NaSingle-groupOpen-labelTreatment
Summary
Primary objective: To assess the potential effect of oral Clarithromycin on the single-dose pharmacokinetics of Givinostat. Secondary objective: To assess the safety and tolerability of concomitant administration of Givinostat plus Clarithromycin.
Timeline
- Start
- 2022-03-21
- Primary completion
- 2022-05-08
- Completion
- 2022-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | Oral |
| Subject | Givinostat | Small molecule | 50 mg | Oral |
Indications
No indication recorded.